

**Quantitative assessment of the impact of COVID 19 pandemic on pancreatic surgery: an Italian multicenter analysis of 1,423 cases from 10 tertiary referral centers**

**Journal name:** Updates in Surgery

Giuseppe Quero<sup>a,b,c</sup>, MD; Nicolò Pecorelli<sup>d,e,f</sup>, MD, MSc; Salvatore Paiella<sup>g</sup>, MD; Claudio Fiorillo<sup>a,b</sup>, MD; Maria Chiara Petrone<sup>d,e,f</sup>, MD; Fausto Rosa<sup>a,b,c</sup>, MD, PhD, FACS; Giovanni Capretti<sup>h,i</sup>, MD; Vito Laterza<sup>a,b</sup>, MD; Emanuele Kauffmann<sup>j</sup>, MD; Sara Nobile<sup>g</sup>, MD; Giovanni Butturini<sup>k</sup>, MD; Giovanni Ferrari<sup>l</sup>, MD; Andrea Coratti<sup>m</sup>, MD; Riccardo Casadei<sup>n</sup>, MD; Vincenzo Mazzaferro<sup>o</sup>, MD; Ugo Boggi<sup>j\*</sup>, MD; Alessandro Zerbi<sup>h,i\*</sup>, MD; Roberto Salvia<sup>g\*</sup>, MD; Massimo Falconi<sup>d,e,f\*</sup>, MD; Sergio Alfieri<sup>a,b,c\*</sup>, MD

<sup>a</sup> Gemelli Pancreatic Center, Fondazione Policlinico Universitario “Agostino Gemelli” IRCCS; Largo Agostino Gemelli, 8, 00168, Rome (Italy)

<sup>b</sup> CRMPG (Advanced Pancreatic Research Center), Largo Agostino Gemelli, 8, 00168, Rome (Italy)

<sup>c</sup> Università Cattolica del Sacro Cuore di Roma, Largo Francesco Vito 1, 00168, Rome (Italy)

<sup>d</sup> Division of Pancreatic Surgery, Pancreas Translational & Clinical Research Center, IRCCS San Raffaele Scientific Institute, Milan, Italy

<sup>e</sup> Vita-Salute San Raffaele University, Milan Italy

<sup>f</sup> Pancreato-Biliary Endoscopy and EUS Division, Pancreas Translational & Clinical Research Center, IRCCS San Raffaele Scientific Institute, Milan, Italy

<sup>g</sup> Department of General and Pancreatic Surgery, The Pancreas Institute, University of Verona Hospital Trust, Italy

<sup>h</sup> Humanitas Clinical and Research Center – IRCCS - Rozzano (MI)

<sup>i</sup>Humanitas University, Department of Biomedical Sciences - Pieve Emanuele (MI)

<sup>j</sup>Chirurgia Generale Universitaria dell'Ospedale di Cisanello, Via Paradisa, 2, 56124 Pisa (Italy)

<sup>k</sup>Casa di Cura Pederzoli, Via Monte Baldo 24, 37019 Peschiera del Garda, Verona (Italy)

<sup>l</sup>ASST Grande Ospedale Metropolitano Niguarda, Division of Minimally-invasive Surgical Oncology, Piazza Ospedale Maggiore, 3 20162, Milan, Italy

<sup>m</sup>Division of Surgical Oncology and Robotics, Department of Oncology, Careggi University Hospital, Florence, Italy

<sup>n</sup>Department of Medical and Surgical Sciences, University of Bologna, Bologna

<sup>o</sup>HPB Surgery and Liver Transplantation, Department of Oncology, University of Milan, Milan, Italy and Istituto Nazionale Tumori, Fondazione IRCCS, Milan, Italy

**Corresponding author:**

Claudio Fiorillo, MD

Gemelli Pancreatic Center

Department of Surgery, Fondazione Policlinico Universitario "Agostino Gemelli", IRCCS

Largo Agostino Gemelli, 8

00168 Rome, Italy

tel.: +39 06 30 15 51 33

fax: +39 06 30 15 65 20

e-mail: [claudio.fiorillo@policlinicogemelli.it](mailto:claudio.fiorillo@policlinicogemelli.it)

<b>Online resource 4. Pancreatic diseases treated during the two semesters of analysis</b>			
	<b>1<sup>st</sup> January-30<sup>th</sup> June 2019</b>	<b>1<sup>st</sup> January-30<sup>th</sup> June 2020</b>	<b>p</b>
<b>Histotype, n (%)</b>			
<i>Ductal adenocarcinoma</i>	414 (52.7)	375 (58.7)	0.16
<i>Ductal-mucinous adenocarcinoma</i>	1 (0.1)	1 (0.2)	1
<i>Ductal-squamous adenocarcinoma</i>	2 (0.2)	4 (0.6)	0.41
<i>Undifferentiated carcinoma</i>	5 (0.6)	1 (0.2)	0.1
<i>Undifferentiated carcinoma with osteoclast-like giant cells</i>	0	1 (0.2)	-
<i>Acinar cell carcinoma</i>	3 (0.4)	1 (0.2)	0.31
<i>Pancreatoblastoma</i>	1 (0.1)	0	-
<i>Solid pseudopapillary neoplasms</i>	11 (1.4)	10 (1.6)	0.82
<i>Ampullary adenocarcinoma</i>	61 (7.8)	38 (5.9)	<b>0.02</b>
<i>Cholangiocarcinoma</i>	25 (3.2)	30 (4.7)	0.5
<i>Deuodenal adenocarcinoma</i>	7 (0.9)	7 (1)	1
<i>Pancreatic metastases</i>	15 (1.9)	12 (1.9)	0.56
<i>Dysplasia</i>	1 (0.1)	3 (0.5)	0.31
<i>IPMN</i>	67 (8.5)	29 (4.5)	<b>&lt;0.0001</b>
<i>IPMC</i>	7 (0.9)	6 (0.9)	0.78
<i>Pancreatic neuroendocrine neoplasms (G1, G2,G3,)</i>	96 (12.2)	67 (10.5)	<b>0.02</b>
<i>Pancreatic neuroendocrine carcinoma</i>	2 (0.2)	0	
<i>Mixed neuroendocrine-non-neuroendocrine neoplasms</i>	4 (0.5)	2 (0.3)	0.41
<i>Ampullary neuroendocrine neoplasms</i>	2 (0.2)	0	-
<i>Nesidioblastosis</i>	0	1 (0.2)	-
<i>Inflammatory diseases</i>	8 (1)	15 (2.3)	0.14
<i>Pancreatic cyst</i>	4 (0.5)	0	-
<i>Serous cystadenoma</i>	12 (1.5)	5 (0.8)	0.09
<i>Serous cystadenocarcinoma</i>	0	1 (0.2)	-
<i>Mucinous cystadenoma</i>	22 (2.8)	19 (2.9)	0.63
<i>GIST</i>	5 (0.6)	4 (0.6)	0.73
<i>Heterotopic lesions</i>	3 (0.4)	1 (0.2)	0.31
<i>Duodenal benign lesions</i>	4 (0.5)	2 (0.3)	0.41
<i>Benign mesenchymal lesions</i>	1 (0.1)	1 (0.2)	1

<i>Malignant mesenchymal lesions</i>	0	1 (0.2)	-
<i>Lymphatic benign lesions</i>	1 (0.1)	1 (0.2)	1
<i>Lymphatic malignant lesions</i>	1 (0.1)	0	-